Should
patents on gene cell sequences follow the classical model of patent claims or be limited to specific uses («purpose - bound protection»)?
Not exact matches
Boston Children's Hospital has offered non-exclusive licenses to for - profit entities
on a
patent developed by Orkin's laboratory regarding BCL11A, a genetic switch regulating hemoglobin production that is expected to form the basis of clinical trials for
gene therapy and
gene editing for sickle
cell disease and thalassemia.
He provides advice and recommendations
on issues relating to genetic testing, screening,
gene patents, genetic privacy, stem
cell therapy and the translation of new knowledge and technologies to improve in health services.
A
patent application has been filed and testing is underway
on the protein — called HT - TALENs (short for HIV - targeted transcription activator - like effector nucleases)-- which uses a newly developed
gene - editing technique to rid the body's
cells of the immunodeficiency virus before it has a chance to multiply and possibly develop into AIDS.